Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Atlanta, Georgia

CNS medication trials in Atlanta, GA

68 CNS medication studies are recruiting participants at sites in Atlanta as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Atlanta at a glance

  • 68 studies are recruiting at a site in Atlanta.
  • By phase: Early Phase 1 (2), Phase 1 (2), Phase 2 (18), Phase 3 (37), Phase 4 (7), No phase (2). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (57), university, hospital or other (11).
  • By research area: Depression (24), Schizophrenia (18), Migraine (6), Multiple Sclerosis (6), Bipolar Disorder (5), Parkinson's Disease (4), ADHD (3), Epilepsy (2).
  • Most recent update to one of these records: November 17, 2026.

Depression studies recruiting in Atlanta

Basic details from each study's public record (the 30 most recently updated of 68). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Cenexel Atlanta (ACMR)
    Registry record
    NCT07226661 · updated
  2. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    Emory University
    Registry record
    NCT07002034 · updated
  3. A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Seaport Therapeutics
    Study site
    Seaport Investigator Site
    Registry record
    NCT07065240 · updated
  4. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    CenExel - Atlanta Center for Medical Research
    Registry record
    NCT07592689 · updated
  5. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    The Emory Clinic
    Registry record
    NCT05850689 · updated
  6. Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

    • Phase 3
    • Ages 10 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    CenExeli Research LLC
    Registry record
    NCT06372964 · updated
  7. Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Agile Clinical Research Trials, LLC
    Registry record
    NCT06559306 · updated
  8. A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Peachford Hospital-Atlanta Behavioral Research
    Registry record
    NCT07227454 · updated
  9. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Agile Clinical Research Trials, LLC
    Registry record
    NCT07573176 · updated
  10. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Atlanta, GA on ClinicalTrials.gov.

Schizophrenia studies recruiting in Atlanta

  1. Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

    • Phase 3
    • Ages 18 to 55
    • All sexes
    Sponsor
    Minerva Neurosciences
    Study site
    Atlanta Center for Medical Research, LLC
    Registry record
    NCT07565428 · updated
  2. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    • Phase 3
    • Ages 13 to 17
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Atlanta Center for Medical Research
    Registry record
    NCT07288567 · updated
  3. A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Atlanta Center for Medical Research
    Registry record
    NCT07424404 · updated
  4. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study sites
    Atlanta Center for Medical Research · CenExeli Research LLC
    Registry record
    NCT06229210 · updated
  5. A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

    • Phase 1
    • Ages 18 to 60
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Synexus Clinical Research US Inc
    Registry record
    NCT07615426 · updated
  6. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Atlanta Center for Medical Research
    Registry record
    NCT07686263 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Atlanta, GA on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Atlanta

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Atlanta Center for Medical Research
    Registry record
    NCT06951711 · updated
  2. A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Atlanta Center for Medical Research
    Registry record
    NCT07286175 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Atlanta, GA on ClinicalTrials.gov.

ADHD studies recruiting in Atlanta

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Atlanta, GA on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Atlanta

  1. A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Winship Cancer Institute of Emory University ( Site 5005)
    Registry record
    NCT07216703 · updated
  2. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Grady Memorial Hospital
    Registry record
    NCT07174310 · updated
  3. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    Emory University
    Registry record
    NCT06680830 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Atlanta, GA on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Atlanta

  1. A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Genentech, Inc.
    Study site
    Atlanta Neuroscience Institute
    Registry record
    NCT07609719 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Atlanta, GA on ClinicalTrials.gov.

Epilepsy studies recruiting in Atlanta

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Registry record
    NCT07563881 · updated
  2. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study sites
    Children's Healthcare of Atlanta · Emory Brain Health Center
    Registry record
    NCT05667142 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Atlanta, GA on ClinicalTrials.gov.

Migraine studies recruiting in Atlanta

  1. Study of EVO756 in Adults With Migraine

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Evommune, Inc.
    Study site
    Clinical Integrative Research Center of Atlanta
    Registry record
    NCT07616128 · updated
  2. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Clinical Integrative Research Center of Atlanta
    Registry record
    NCT07816367 · updated
  3. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    DelRicht Research
    Registry record
    NCT07645924 · updated
  4. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    DelRicht Research
    Registry record
    NCT07674654 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Atlanta, GA on ClinicalTrials.gov.

Ask about studies near Atlanta

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Georgia

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call